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Systemic fungal infectionAmphotericinB (AmB), apoorly soluble and toxic antifungaldrug,wasencapsulated intopolymericmicelles
self-assembled from phenylboronic acid-functionalized polycarbonate/PEG (PEG-PBC) and urea-
functionalized polycarbonate/PEG (PEG-PUC) diblock copolymers via hydrogen-bonding, boronate ester
bond, and/or ionic interactions between the boronic acid group in the micellar core and amine group in
AmB. Three micellar formulations were prepared: AmB/B micelles using PEG-PBC, AmB/U micelles using
PEG-PUC andAmB/B+Umixedmicelles using 1:1 molar ratio of PEG-PBC and PEG-PUC. The average particle
sizes of the micelles were in the range of 54.4–84.8 nm with narrow size distribution and zeta potentials
close to neutral. UV–Vis absorption analysis indicated that AmB/B micelles significantly reduced AmB
aggregation status due to the interactions between AmB and the micellar core, while Fungizone and
AmB/U micelles had no effect. AmB/B+U mixed micelles exerted an intermediate effect. Both AmB/B
micelles and AmB/B+U mixed micelles showed sustained drug release, with 48.6 ± 2.1% and 59.2 ± 1.8%
AmB released respectively after 24 h under sink conditions, while AmB/Umicelles displayed a burst release
profile. All AmB-loaded micelles showed comparable antifungal activity to free AmB or Fungizone, while
AmB/B micelles and AmB/B+U mixed micelles were much less hemolytic than other formulations.
Histological examination showed that AmB/B and AmB/B+U micelles led to a significantly lower number
of apoptotic cells in the kidneys compared to Fungizone, suggesting reducednephrotoxicity of themicellar
formulations in vivo. These phenylboronic acid-functionalized polymeric micelle systems are promising
drug carriers for AmB to reduce non-specific toxicities without compromise in antifungal activity.
Statement of Significance
There is a pressing need for a novel and cost-effective delivery system to reduce the toxicity induced by
the antifungal agent, amphotericin B (AmB). In this study, phenylboronic acid-functionalized polycarbon-
ate/PEG diblock copolymers were used to fabricate micelles for improved AmB-micelle interaction via the
manipulation of hydrogen-bonding, boronate ester bond, ionic and hydrophobic interactions. Compared
to free AmB and Fungizone, the resultant micellar systems displayed improved stability while reducing
non-specific toxicities without a compromise in antifungal activity. These findings demonstrate the
potential of biodegradable functional polycarbonate micellar systems as promising carriers of AmB for
the treatment of systemic fungal infections.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction mised patients [1]. The polyene macrolide antibiotic amphotericinSystemic fungal infections are posing a global health concern
due to the significant morbidity and mortality in immunocompro-B (AmB) exhibits a broad-spectrum antifungal activity and is a cru-
cial therapeutic option for the treatment of severe systemic myco-
sis [2]. However, the life-saving benefits of AmB are impaired by its
toxicities to normal tissues, which induce various side effects,
including infusion-related toxicity and chronic toxicities, such as
nephrotoxicity, cardiotoxicity, hepatoxicity, leukopenia and
thrombocytopenia [3]. The toxicities of AmB are associated with
212 Y. Wang et al. / Acta Biomaterialia 46 (2016) 211–220the formation of soluble aggregates due to its amphoteric nature.
The selectivity of AmB between fungal and mammalian cells
depends on the aggregation state of AmB and the nature of mem-
brane sterol. Monomeric AmB is the only form present at low AmB
concentration, while the aggregated form appears when AmB con-
centration increases [4]. Both monomeric and aggregated forms of
AmB interact with ergosterol in fungal membranes, forming trans-
membrane pores through which a leakage of ions and metabolites
occurs. However, only aggregated forms produce such pores in
mammalian cell membranes that are rich in cholesterol [5]. Cur-
rently available formulations of AmB for clinical applications
include Fungizone and lipid formulations consisting of AmBi-
some, AmphotecTM and Abelcet. Fungizone is essentially a col-
loidal dispersion in which AmB is solubilized with sodium
deoxycholate; however, AmB is released rapidly from Fungizone
in the aggregated form upon dilution in plasma, leading to severe
side effects, which limit its widespread clinical applications [6,7].
Although lipid formulations of AmB are less toxic than Fungizone,
the side effects and pharmacokinetic profiles of each formulation
are highly variable and pose difficulties in dose titration [8,9]. In
general, the high cost and dose requirements are major limitations
of currently available lipid-based systems [10]. Thus, there is an
imperative unmet need to develop innovative and cost-effective
formulations of AmB with reduced toxicity.
Polymeric micelles are promising drug carriers for the delivery
of hydrophobic therapeutics. Due to the unique core/shell struc-
ture, polymeric micelles not only enhance water solubility but also
reduce non-specific toxicities of loaded drugs [11]. In addition, var-
ious covalent/non-covalent interactions can be introduced into
polymeric micelles systems to improve drug-micelle interaction
and drug-loading capacity, enhance systemic stability and achieve
controlled drug release [11]. Some reports have shown that loading
AmB into micelles could reduce the aggregation forms of AmB, thus
significantly lowering the toxicities [10,12–15]. For instance,
Adams and his coworker encapsulated AmB into micelles using
poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide) having
acyl side chains, and demonstrated a reduced degree of aggrega-
tion and hemolysis compared with free AmB in solution due to
the interaction between AmB and the acyl chains [16].
In recent years, polycarbonate polymers have been widely
explored in drug delivery due to their biodegradability, low toxic-
ity in vivo, and easy functionalization [17]. In this study, polymeric
micelles were developed using phenylboronic acid-functionalized
polycarbonate/PEG diblock copolymers for the delivery of AmB to
reduce non-specific toxicity without appreciable loss in antifungal
activity. In an attempt to inhibit self-aggregation of AmB and
achieve controlled drug release, boronic acid groups included
may potentially interact with AmB via hydrogen-bonding and ionic
interactions. Boronate ester bond formation via phenylboronic acid
interaction with diols may also contribute to this effect [18]. As a
comparison, urea-functionalized polycarbonate/PEG diblock
copolymer (PEG-PUC) was employed to prepare AmB-loaded and
mixed micelles with PEG-PBC. The AmB-loaded micelles were pre-
pared using a sonication-dialysis method and characterized via
particle size, size distribution, TEM and in vitro stability. Addition-
ally, the in vitro drug release and aggregation status of AmB in the
different micelle formulations were assessed. Lastly, antifungal
effects and hemolytic activity were evaluated and compared with
free AmB as well as Fungizone in vitro.
2. Materials and methods
2.1. Materials
Amphotericin B, dimethylsulfoxide (DMSO, synthesis grade,
99.9%), Tween 80, Triton X-100 and Mueller Hinton agar wereacquired from Sigma-Aldrich (St Louis, MO, USA). Fungizone
was purchased from Invitrogen Gibco containing 250 lg of ampho-
tericin B and 205 lg of sodium deoxycholate per mL of distilled
water. YM broth (Acumedia No. 7363A) was purchased from Neo-
gen Corporation (Michigan, USA). Phosphate-buffered saline (PBS)
solution at 10  concentration was purchased from Vivantis Tech-
nologies (Malaysia) and diluted appropriately before use. Methyl-
PEG (mPEG) (Mn 10000 g/mol, polydispersity index-PDI: 1.10)
was obtained from Polymer Source Inc. (Canada), lyophilized and
transferred to a glove-box one day prior to use. 1,8-Diazabicyclo[
5,4,0]undec-7-ene (DBU) was dried over CaH2 overnight, and dried
DBU was obtained after vacuum distillation before being trans-
ferred to a glove-box prior to use. 6 mm antibiotic assay discs
(2017-006) were purchased from GE Healthcare Life Sciences
(Singapore). Rat red blood cells (rRBCs) were obtained from the
Animal Handling Units of the Biomedical Research Centers (AHU,
BRC, Singapore).
2.2. Synthesis and characterization of monomers and diblock
copolymers
The synthesis and characterization of PEG-PUC were performed
using a previously published protocol [19]. The details for synthe-
sizing phenylboronic acid-functionalized monomer (MTC-PBA) and
PEG-PBC were provided below (Scheme 1). All polymerization
reactions were carried out in a glove-box under nitrogen
atmosphere.
2.2.1. MTC-PBA
In a dry two-neck 500 mL round bottom flask equipped with
a stir bar, MTC-OH (3.08 g, 19.3 mmol) was dissolved in dry
tetrahydrofuran (THF) (50 mL) with 5–8 drops of dimethylformamide
(DMF). Subsequently, oxalyl chloride (3.3 mL) was added in one
shot (pure form), followed by additional of THF (20 mL). The
solution was stirred for 90 min, after which volatiles were dried
under a strong flow of nitrogen to yield a pale yellow solid
intermediate (5-chlorocarboxy-5-methyl-1,3-dioxan-2-one, MTC-Cl).
The solid was then subjected to heat at 60 C for 2–3 min
for removal of the residual solvent, and re-dissolved in dry
dichloromethane (CH2Cl2, 50 mL). The flask was immersed in an
ice bath at 0 C. A mixture of 4-(hydroxymethyl) phenylboronic
acid pinacol ester (4.19 g, 17.88 mmol) and triethylamine
(1.77 mL, 19.3 mmol) were dissolved in dry CH2Cl2 (50 mL), which
was added dropwise to the flask over a duration of 30 min. The
flask was removed out of the ice batch, allowing the reaction to
proceed at room temperature (22 C) for 2.5 h under stirring.
The reaction was then quenched by addition of 50 mL of brine,
and the organic phase was collected after separation. After removal
of the solvent, the crude product was purified by silica-gel flash
column chromatography via a hexane-ethyl acetate solvent system
(gradient elution up to 20% vol. ethyl acetate) followed by a solvent
switch to dichloromethane-ethyl acetate (gradient elution up to 20%
vol. ethyl acetate) to yield MTC-PBA as a white solid. The product
was further purified by recrystallization. The solid was dissolved in
50 mL of diethyl ether and the residues were filtered. The filtrate
was dried and subsequently dissolved in 2 mL of diethyl ether and
ethyl acetate (1 mL each), followed by addition of 50 mL of hexane.
The crystals were allowed to form at room temperature for 1 day, and
subsequently obtained by washing the crystals with cold hexane.
1H NMR (400 MHz, CDCl3, 22 C): d 7.83–7.32 (m, 4H, AC6H4B@),
5.22 (s, 2H, ACH2C6H4A), 4.72–4.18 (m, 4H, ACOOCH2A), 1.34
(s, 12H, AOC(CH3)4COA), 1.32 (m, 3H, ACH3).
2.2.2. PEG-PBC
In a glove-box, 0.222 g (0.022 mmol) of 10 kDa mPEG-OH initia-
tor and 0.376 g (1 mmol) of MTC-PBA were charged in a 20 mL
Scheme 1. Synthesis of diblock copolymer of PEG-PBC.
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and the monomer concentration was adjusted to 2 M. Once the
initiator and monomer were completely dissolved, 8.3 lL
(0.06 mmol) of DBU was added to initiate the polymerization. After
3.5 h of stirring at room temperature, the reaction was quenched
with 30 mg of benzoic acid under stirring for 5 min. Subsequently,
the polymer intermediate was purified via precipitation twice in
cold diethyl ether, and dried on a vacuum line until a constant
weight was achieved. 1H NMR (400 MHz, CDCl3, 22 C): d
7.83–7.27 (m, 48H, AC6H4B@), 5.23–5.02 (m, 24H, ACH2C6H4A),
4.49–4.13 (m, 48H, ACOOCH2A), 3.84–3.43 (m, 908H, AOCH2CH2-
A from 10 kDa PEG), 3.38 (s, 3H, CH3-PEG-), 1.39–1.27 (m, 144H,
AOC(CH3)4COA), 1.26–1.16 (m, 36H, ACH3).
The protected polymer was then deprotected by dissolving in
14 mL of methanol and THF (1:1). Ten equivalents (with respect
to mols of protected phenylboronic pinacol pendant groups) of
benzene-1,4-diboronic acid and Amberlyst 15 acidic resins were
added to a 50 mL round bottom flask containing the protected
polymer. The flask was subsequently heated to 50 C with over-
night stirring. After that, the solvents were removed under
vacuum. The deprotected polymer was dissolved in 10 mL of iso-
propanol and acetonitrile (1:1) and placed in a dialysis bag of
1000 MW cut-off. Dialysis was carried out for 2 days at room tem-
perature using 1:1 isopropanol and acetonitrile. Finally, the sol-
vents were removed, and the polymer was lyophilized to obtain
an off-white polymer. 1H NMR (400 MHz, DMSO-d6, 22 C): d
8.22–7.88 (m, 24H, AB(OH)2), 7.84–7.15 (m, 48H, AC6H4B@),
5.23–4.96 (m, 24H, ACH2C6H4A), 4.46–4.02 (m, 48H, ACOOCH2A),
3.71.-3.14 (m, 909H, AOCH2CH2A from 10 kDa PEG), 3.23 (s, 3H,
CH3-PEG-), 1.25–1.05 (m, 36H, ACH3).2.2.3. Characterization of PEG-PBC
1H NMR spectrum was obtained on a Bruker Avance 400
instrument at 400 MHz. Gel permeation chromatography (GPC)
was performed in THF using a Waters system equipped with four
increasing pore size (100, 1000, 105, and 106 Å), a Waters 410
differential refractometer, and a 996 photodiode array detector.
The system was calibrated with polystyrene standards.2.3. Determination of critical micelle concentration (CMC)
The CMC values of PEG-PBC, PEG-PUC and the mixture of PEG-
PBC and PEG-PUC were measured using previously reported
method [20]. Briefly, 10 lL of pyrene acetone solution at concen-
tration of 6.16  105 M was added into glass vials and allowed
the acetone to evaporate under room temperature. Subsequently,
1 mL of polymer solution at concentrations ranging from 0.01 to
1000 mg/L was added into each vial. After mixing, the mixture
solutions were incubated overnight and then scanned from 300
to 360 nm with an emission wavelength of 395 nm to acquire exci-
tation spectra using a LS50B luminescence spectrometer (PerkinElmer, U.S.A). The excitation and emission bandwidths were both
set at 2.5 nm. The CMC value was calculated based on the curve
plotted using the intensity ratios of I337/I334 for different polymer
concentrations as a function of polymer concentration.2.4. Micelles preparation and characterizations
AmB-loaded micelles were formed using the sonication-dialysis
method (Scheme 2). Briefly, 5 mg of AmB was dissolved in 1 mL of
DMSO. Subsequently this solution was added to 1 mL of DMSO
containing 10 mg of polymers (PEG-PBC, PEG-PUC or mixture of
PEG-PBC and PEG-PUC at 1:1 molar ratio) and incubated at room
temperature for 30 min. The mixture solution was added dropwise
into 10 mL DI water within 2 min while being sonicated (130 W,
Vibra Cell VCX 130) in an ice bath. The sample was then subjected
to dialysis against DI water for 48 h to remove free AmB and
organic solvent. The water was changed at 6, 24 and 30 h. The
micelles were collected for further analysis. The concentration of
copolymers was approximately 0.7 mg/mL in the micellar
formulations.
The particle size, size distribution and zeta potential of the
micelles were characterized by DTS zetasizer Nano (Malvern
Instruments, UK). The morphology of the micelles was visualized
by transmission electron microscopy (TEM, FEI Tecnai G2 F20 elec-
tron microscopy) using an acceleration voltage of 200 keV. Briefly,
one drop of micelle solution (4 lL) was added onto a Formvar
coated 200 mesh copper grid (Ted Pella Inc., U.S.A.). After 1 min,
the excess solution was removed by filter paper. Same volume of
phosphotungstic acid (1%) was added onto the grid, and the excess
solution removed after 1 min. The grid was left to dry under room
temperature.
The stability of the micelles was evaluated by monitoring the
changes of particle size as a function of time at 200 mg/L in PBS
(pH 7.4) at 4 C and in PBS (pH 7.4) containing 10% FBS at 37 C,
respectively. The change of scattered light intensity, in the pres-
ence of sodium dodecyl sulfate (SDS, 2.23 mg/mL) at room temper-
ature, was recorded using DTS zetasizer Nano at predetermined
time points to evaluate the kinetic stability of the micelles.2.5. Determination of encapsulation efficiency and study of
aggregation state of AmB in the micelles
The drug encapsulation efficiency (EE%) of the micelles was
determined using High-performance liquid chromatography
(HPLC) (Shimadzu, Kyoto) according to a published protocol [21]
and calculated using the following formula: EE% = (mass of drug
loaded in micelles/mass of initial loaded drug)  100%.
The aggregation state of AmB in micelles was analyzed by using
UV–Vis spectroscopy (Ultrospec 2100 Pro, Amersham). The AmB
concentration was adjusted to 25 mg/L. As comparison, solution
of Fungizone diluted in PBS and AmB dissolved in DMSO were
Scheme 2. Schematic showing of AmB-loaded micelles preparation using PEG-PBC and PEG-PUC.
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300 to 450 nm.2.6. In vitro drug release
The in vitro release of AmB from micelles was investigated by
dialysis against PBS at pH 7.4 at 37 C. Briefly, AmB-loaded micelle,
Fungizone or free AmB solution (1 mg/L, 2 mL) was introduced
into a dialysis bag (Molecular weight cut-off, 11 kDa) and then
immersed into 20 mL of PBS (pH 7.4) containing 1% tween 80 while
being shaken at 100 rpm. At the predetermined time points, the
release medium was collected and replaced with the same volume
of PBS. The content of AmB release was measured using HPLC.2.7. In vitro antifungal activity
To evaluate the in vitro antifungal activity of various formula-
tions, firstly the minimal inhibitory concentration (MIC) against
C. albicans (ATCC No. 10231) was determined using an established
protocol [22]. Briefly, 100 lL of diluted AmB-containing formula-
tions including micelles, free AmB, Fungizone (AmB concentra-
tions ranged from 0.06–7.8 mg/L) and blank micelle (polymer
concentrations ranged from 3.9–1000 mg/L) solutions, were added
to an equal volume of fungal solution containing approximately
105 CFU/mL in a 96-well plate. The plate was incubated at 37 C
under shaking at a speed of 200 rpm. After 42 h, the optical density
(OD) at 600 nm was read using a microplate reader (TECAN,
Switzerland).
The disk diffusion test was also performed to assess the in vitro
antifungal effects of various formulations [23]. Briefly, the turbidity
of C. albicans culture was adjusted to an OD reading of 0.07. The
yeast solution (300 lL) was spread onto MH agar plate, and
allowed to be absorbed for 10 min. The paper discs (6 mm) pre-
soaked in different samples at a concentration of 31.25 mg/L were
placed gently onto the agar plate. The plate was inverted and incu-
bated at 37 C. The zone diameter of inhibition was measured after24 h of incubation. The disk impregnated with growth media was
used as control.
2.8. Hemolysis assay
To evaluate the toxicity of the AmB-loaded micelles as com-
pared to free AmB and Fungizone, their hemolytic activity was
tested against rat red blood cells (rRBCs) using a previously
reported method with slight modification [24]. The rRBCs were
diluted 25 times with PBS (pH 7.4). Serial two-fold dilution of
the micelles, free AmB and Fungizone was prepared using PBS
(0.39–25 mg/L). The drug solution (250 lL) at different concentra-
tions was gently mixed with an equal volume of the blood suspen-
sion. The mixtures were centrifuged at 4000 g for 5 min after 1 h
incubation at 37 C. After centrifugation, 100 lL of the supernatant
was transferred into a 96-well plate. The rRBCs treated with PBS
served as a negative control while the rRBCs treated with 1%
Triton-X were used as a positive control. The absorbance of hemo-
globin released was read at 576 nm using the microplate reader
(TECAN, Switzerland). The hemolysis was calculated based on
following formula: Hemolysis (%) = [(O.D.576nm of treated sample 
O.D.576nm of negative control)/(O.D.576nm of positive sample  O.
D.576nm of negative control)]  100%.
In addition, the hemolysis induced by AmB-loaded micelles at a
fixed concentration of 12.5 mg/L and blank micelles was also mon-
itored as a function of time. The samples were incubated at 37 C
and the hemolysis was determined at predetermined time points
(1, 2, 4, and 6 h). Each test was carried out in 4 replicates and
reproduced twice.
2.9. Study of in vivo nephrotoxicity
The in vivo nephrotoxicity of Fungizone and AmB-loaded
micelles was evaluated in a mouse model. Briefly, healthy BALB/c
mice (female, body weight 19–25 g) were randomly divided into
4 groups of 3 mice each. AmB/B micelles, AmB/B+U mixed micelles
and Fungizone were injected through tail vein at a dose of
Y. Wang et al. / Acta Biomaterialia 46 (2016) 211–220 2151 mg/kg for 3 consecutive days [25]. Two days after the last injec-
tion, the mice were sacrificed and the kidneys excised. The samples
were fixed using 10% formalin followed by paraffin embedding and
terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) staining. The nuclei were visualized by counter-
staining the slides with hematoxylin. The number of TUNEL-
positive nuclei in 9 representative fields (3 fields from each mouse)
was counted to determine the apoptotic cells in the kidney
sections. The images were acquired using a light microscope
(Olympus, Japan). Animal studies were carried out according to
the protocols approved by the Singapore Biological Research
Center (BRC)’s Institutional Animal Care and Use Committee.
2.10. Statistical analysis
Data were presented as means ± standard deviation (SD). Data
were analyzed using one-way ANOVA followed by Tukey’s post
hoc analysis (Graphpad, Prism, USA). The difference betweenFig. 1. 1H NMR of (a) pinocal protecvalues for the treatments was considered to be statistically signif-
icant at p < 0.05.
3. Results and discussion
3.1. Synthesis of phenylboronic acid-functionalized monomer and
diblock copolymer
MTC-urea monomer and diblock copolymer PEG-PUC were pre-
pared following previously established protocols [19]. The phenyl-
boronic acid-functionalized monomer (MTC-PBA) was synthesized
by direct coupling of MTC-Cl and 4-hydroxymethyl phenylboronic
pinacol in the presence of trimethylamine with a yield of 52% after
column and recrystallization. The diblock copolymer, PEG-PBC,
was synthesized via metal-free organocatalytic ROP of MTC-PBA
using mPEG of 10 kDa as a macroinitiator in the presence of the
catalyst DBU (Fig. 1a) for 3.5 h. 1H NMR integration values of
monomers relative to the PEG initiator correlated well, confirmingted PEG-PBC and (b) PEG-PBC.
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initial monomer to initiator feed ratio. In addition, the proton
NMR analysis displayed all the peaks associated with both initiator
and monomers (Fig. 1a). From the GPC results, the polymer had
narrow molecular weight distribution (PDI 1.16). The pinacol pro-
tected phenylboronic acid groups in the polymers were depro-
tected at 50 C using benzene-1,4-diboronic acid and acidic
resins. The proton NMR analysis of the deprotected polymer
showed 97% deprotection of the pinacol protecting groups, demon-
strating efficient deprotection. In addition, the presence of a new
distinct peak at d 8.05 ppm confirmed the presence of hydroxyl
groups, which correlated to the deprotected phenylboronic acid
pendant groups (Fig. 1b).
3.2. Characterization of AmB-loaded micelles
CMC refers to the lowest concentration for copolymer to self-
assemble into micelles, a parameter reflecting thermodynamic sta-
bility [20]. The PEG-PBC polymer, the mixture of PEG-PUC/PEG-PBC
(1:1 molar ratio) and PEG-PUC polymer presented low CMC values
(8.0, 4.3 and 3.8 mg/L), indicating the micelles formed by these
polymers potentially have high thermodynamic stability. Blank
micelles were formed by self-assembly in water with small particle
size and low PDI based on the dynamic light scattering (DLS) anal-
ysis (Fig. 2a). The AmB-loaded micelles, i.e., AmB/B micelles, AmB/B
+Umixedmicelles, and AmB/Umicelles, showed slightly larger par-
ticle sizes than the corresponding blank micelles, which were all
well below 100 nm, ideal for in vivo application (Fig. 2a). All the
AmB-loaded micelles demonstrated narrow size distribution, as
suggested by the PDI values: 0.17 ± 0.01, 0.18 ± 0.01 andFig. 2. Characterization of micelles: (a) Size, PDI, zeta potential, encapsulation efficiency
TEM images: (b) AmB/B micelles, (c) AmB/B+U mixed micelles, and (d). AmB/U micelles0.16 ± 0.04 for AmB/B, AmB/B+Uand AmB/U micelles, respectively
(Fig. 2a). The morphologies of the micelles were visually observed
under TEM. The dimensions of the micelles from the TEM analysis
were generally in agreement with the DLS analysis (Fig. 2b–d).
All the micelles had zeta potential values close to neutral
(1.6 ± 2.0 mV, 2.4 ± 1.5 mV and 2.0 ± 0.5 mV for AmB/B, AmB/
B+U and AmB/U micelles, respectively) (Fig. 2a). The electrically
neutral surface of nanoparticles is ideal for in vivo systemic applica-
tion to avoid aggregate formation with serum proteins typically
observedwith highly cationic nanoparticles, as well as rapid uptake
by phagocytic cells resulting in fast clearance from the blood
observed with highly anionic counterparts [26,27]. In addition, as
shown in Fig. 3a and b, AmB/B micelles and AmB/B+U mixed
micelles exhibited higher stability in both PBS (pH 7.4, 4 C) and
serum-containing PBS (pH 7.4, 37 C) over 14 days and 5 days,
respectively, as compared to AmB/U micelles. In the presence of
SDS which acted as a destabilizing agent, AmB/B micelles displayed
significantly greater kinetic stability than AmB/B+Umixed micelles
and AmB/U micelles (relative intensity at 48 h: 74.1 ± 0.4% vs
45.8 ± 1.2% and 6.6 ± 0.1%) (Fig. 3c). The phenylboronic acid groups
in PEG-PBC could form hydrogen-bonding, boronate ester bond and
ionic interactions with amine group in AmB, thus enhancing stabil-
ity of AmB-loaded micelles. However, the urea functional groups in
the PEG-PUC had strong tendency to undergo self-association via
hydrogen-bonding [28,29]; consequently resulting in reduced
interactions between the PEG-PUC polymer and AmB. In addition,
urea groupmight competewith amine group in AmB for interacting
with boronic acid via hydrogen-bonding interaction, which might
be the reason for the compromised stability of AmB/B+U micelles
as compared to AmB/B micelles.and CMC for AmB-loaded micelles and blank micelles; Morphology observed under
, scale bar: 100 nm.
Fig. 3. Stability of various AmB-loaded micelles in PBS (pH 7.4) at 4 C (a), in 10% FBS containing PBS (pH 7.4) at 37 C (b), and in the presence of SDS (c). Error bars obtained
are smaller than the marker.
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micelles
All the micelles displayed satisfactory drug encapsulation effi-
ciencies: 66.4 ± 3.6%, 72.2 ± 4.4% and 76.4 ± 1.4% for AmB/B
micelles, AmB/B+U mixed micelles and AmB/U micelles, respec-
tively (Fig. 2a). As the absorption spectrum of AmB is highly sensi-
tive to its local environment [30], the aggregation state of AmB was
determined by absorption spectroscopy. Fig. 4 shows the UV spec-
tra of AmB in Fungizone, in DMSO and in various micelles. Band IV
located at 407–419 nm is the characteristic peak for monomeric
form of AmB, while Band I at approximately 330–340 nm repre-
sents the aggregated form [8]. As can be seen from Fig. 3, the spec-
tra of AmB DMSO solution demonstrated the non-aggregated state
of AmB with prominent bands II, III and IV at 371, 391, and 414 nm,
respectively. In contrast, AmB was highly aggregated in Fungi-
zone, resulting in a loss of monomer absorbance at 414 nm (Band
IV) and an increased absorbance at 329 nm (Band I). A similar spec-
tra pattern was observed for AmB/U micelles, demonstrating that
due to the poor interaction between urea functional groups and
AmB, encapsulation of AmB using PEG-PUC polymer alone failed
to reduce the aggregation extent of the drug. Whereas for AmB/B
micelles and AmB/B+U mixed micelles, Band I (329 nm) was found
to have red-shifted towards 345–355 nm region and merged par-
tially with Band II, indicating a reduction in AmB self-aggregation
[31]. These results were supported by enhanced monomer absorp-
tion as shown by the increased intensity of band IV for AmB/BFig. 4. Absorbance spectra of AmB-loaded micmicelles and AmB/B+U mixed micelles. The ratio of intensity of
band I to band IV (i.e., I/IV ratio) was used to evaluate the degree
of AmB aggregation [32]. The I/IV ratios for Fungizone and
AmB/U micelles were as high as 6.4 and 6.3, respectively, while
for AmB/B micelles, the ratio dropped drastically to 1.1. This indi-
cates that compared to Fungizone, AmB/B micelles significantly
reduced the aggregation status of AmB, while AmB/U micelles
had no effect. AmB/B+U mixed micelles, however, exerted an inter-
mediate effect with a ratio of 2.4. These findings suggest that the
aggregation state of AMB is dependent on the presence of phenyl-
boronic acid functional groups which serve to bind AmB in its
monomeric state via hydrogen-bonding, boronate ester bonding,
and ionic interaction in the micellar formulations. The reduction
in aggregation state of AmB in the micelles is potentially beneficial
for systemic application due to lowered cytotoxicities.
3.4. In vitro drug release
In vitro AmB release from various micellar formulations were
determined and compared with free AmB solution and Fungizone.
As shown in Fig. 5, AmB/U micelles displayed a burst drug release
profile similar to that of free AmB and Fungizone over 24 h. The
percentages of AmB released from Fungizone, free AmB and
AmB/U micelle formulations were 98.7 ± 3.4%, 96.2 ± 2.5% and
86.6 ± 1.9%, respectively. In contrast, a sustained drug release pro-
file was observed for both AmB/B micelles and AmB/B+U mixed
micelles, with 48.6 ± 2.1% and 59.2 ± 1.8% of the loaded AmBelles, Fungizone and free AmB in DMSO.
Fig. 5. In vitro release of AmB from AmB/B micelles, AmB/B+Umixed micelles, AmB/
U micelles, free AmB solution and Fungizone in PBS (pH 7.4) at 37 C. Error bars
obtained are smaller than the marker.
Table 1
MICs of free AmB, Fungizone, drug-loaded micelles and blank
micelles against C.albicans.
Formulation MIC (mg/L)
Free AmB 0.24
Fungizone 0.24
AmB/B micelles 0.96
AmB/B+U micelles 0.48
AmB/U micelles 0.24
B blank micelles >1000
B+U blank micelles >1000
U blank micelles >1000
218 Y. Wang et al. / Acta Biomaterialia 46 (2016) 211–220released by 24 h, respectively. These results indicate that physical
entrapment of AmB using the PEG-PUC polymer exerted no control
over drug release. However, due to the interactions between
phenylboronic acid groups and AmB, the release of AmB could be
better controlled, avoiding high drug concentration caused by
rapid release, which is ideal for minimizing the toxicity induced
by exposure of aggregated AmB to mammalian cells.Fig. 6. The zone of inhibition diameters of free AmB, Fungizone and AmB-loaded mic
significant difference.3.5. In vitro antifungal activity
To evaluate the in vitro antifungal activity of various formula-
tions, MIC was determined against C. albicans, which is commonly
susceptible to AmB. As Table 1 shows, AmB/U micelles and AmB/B
+U mixed micelles exhibited comparable MIC values (0.24 mg/L
and 0.48 mg/L) to free AmB and Fungizone (0.24 mg/L for both),
while AmB/B micelles were slightly less effective than the afore-
mentioned formulations (MIC: 0.96 mg/L). The disk diffusion assay
showed similar results (Fig. 6): AmB/U micelles and AmB/B+U
mixed micelles promoted microbial growth inhibition haloes
(diameter: 1.33 ± 0.10 and 1.28 ± 0.05 cm, respectively) that were
comparable to those formed by Fungizone and free AmB (diame-
ter of 1.38 ± 0.05 and 1.43 ± 0.10 cm, respectively) (p > 0.05). AmB/
B micelle induced a halo with diameter of 1.05 ± 0.06 cm, which
was significantly smaller than Fungizone (p < 0.05). A plausible
explanation for the different in vitro antifungal activity of the
AmB-loaded micelles could be associated with the in vitro drug
release profiles. As discussed previously, we attribute the relative
weaker in vitro antifungal effect of AmB/B micelles to slower drug
release resulting from strong interactions between phenylboronic
acid groups and AmB. By adding PEG-PUC polymer to reduce such
interactions, the mixed micelles are expected to display improved
efficacy due to greater drug availability from more rapid drug
release.3.6. In vitro and in vivo toxicity
Hemolysis is a common parameter for evaluating the in vitro
toxicity of AmB [33]. After incubation for 1 h, as shown in Fig. 7a
free AmB, Fungizone and AmB/U micelles (25 mg/L) resulted in
89.7 ± 1.3%, 78.7 ± 1.8% and 52.0 ± 1.0% of hemolysis, respectively,
which can be attributed to both the rapid drug release and high
aggregated AmB content of these formulations. In sharp contrast,
the AmB/B micelles and AmB/B+U mixed micelles caused little or
no hemolysis during the same period. From Fig. 7b, it can be seen
that AmB/B micelles delayed the onset of hemolysis to 4 h at a
low hemolysis degree (10.0 ± 0.3%). Similarly, a delayed onset
(2 h) and reduced degree of hemolysis was also observed for
AmB/B+U mixed micelles as compared to free AmB and Fungi-
zone. In contrast, AmB/U micelles failed to delay the onset of
hemolysis even though it caused slightly lower extent of hemolysiselles (a) and an illustrative image (b). ‘‘***” denotes p < 0.001 and ‘‘ns” denotes no
Fig. 7. Effect of hemolysis of free AmB, Fungizone and AmB-loaded micelles: (a) after 1 h incubation at various concentrations and (b) as function of time at concentration of
12.5 mg/L. Error bars obtained are smaller than the marker.
Fig. 8. TUNEL staining of kidney tissues at 2 days post-injection of AmB-loaded
micelles and Fungizone. Kidney sections obtained from mice treated with (a)
control (PBS); (b) AmB/B micelles; (c) AmB/B+U mixed micelles, and (d) Fungi-
zone; quantification of mean apoptotic bodies per field (objective  20) in kidney
tissues (‘‘⁄⁄⁄⁄” denotes p < 0.0001, ‘‘ns” denotes no significant difference). Scale bar:
100 lm.
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activity, the varied hemolytic profiles for the various AmB-loaded
micelles is likely due to the differences in AmB aggregation degree
and drug release pattern. Despite its relatively weaker antifungal
efficacy, AmB/B micelles presented a favorable toxicity profile in
this study due to the significantly slower drug release and higher
AmB monomer content compared to other formulations. Similar
to the findings of in vitro antifugal study, the AmB/B+U mixed
micelles also demonstrated an intermediate hemolysis profile
due to the reduced interaction between PEG-PBC and AmB caused
by the addition of PEG-PUC.
The nephrotoxicity of Fungizone and AmB-loaded micelles in
mice was investigated using histological examination of kidney
excised from the mice. Using the TUNEL assay, the apoptotic cells
were quantified by counting the brown regions that formed due
to the apoptosis [34]. Fig. 8a–d shows that the treatment of Fungi-
zone led to significantly higher number of apoptotic cells in the
kidneys as compared to AmB/B micelles and AmB/B+U micelles
(p < 0.0001); there was no significant difference among the num-
bers of apoptotic cells caused by AmB/B micelles, AmB/B+U mixed
micelles and control (p > 0.05). These results further proved that
unlike Fungizone, AmB/B micelles and AmB/B+U mixed micelles
did not induce significant nephrotoxicity.4. Conclusion
In this study, we have employed the application of phenyl-
boronic acid-functionalized polycarbonate/PEG diblock copoly-
mers for the encapsulation of poorly soluble and toxic antifungal
drug AmB via hydrogen-bonding, boronate ester formation, ionic
and hydrophobic interactions. Three types of micelles, AmB/B
micelles, AmB/B+U mixed micelles and AmB/U micelles, were
prepared, characterized, and evaluated for their toxicity and anti-
fungal activity. The non-covalent interactions between phenyl-
boronic acid functional groups and AmB conferred AmB/B
micelles an excellent stability under various conditions, a reduc-
tion in AmB aggregation and a controlled drug released profile,
which effectively translated into a delayed and reduced degree of
hemolysis and mitigation of nephrotoxicity. This occurred however
at a slight expense of antifungal activity when compared to free
AmB and Fungizone. On the other hand, urea-functionalized
diblock copolymer, PEG-PUC, displayed a tendency to undergo
self-association due to strong hydrogen-bonding interactions
between urea groups, and resulted in poor interactions with AmB
molecules. This weakened interaction manifested unfavorable
220 Y. Wang et al. / Acta Biomaterialia 46 (2016) 211–220performances of AmB/U micelles, including poor stability, a rapid
drug release and poor control on AmB aggregation. By mixing
PEG-PUC and PEG-PBC in equimolar ratio, we were nonetheless
able to achieve comparable antifungal activity to free AmB and
Fungizone without inducing nephrotoxicity. Through modulating
the physical interactions between polymers and AmB, drug release
and aggregation of AmB could be effectively controlled to improve
toxicity without loss of efficacy. The rational design of AmB micel-
lar formulations using biodegradable and functional polycarbon-
ates is a potential strategy for improving the clinical treatment of
systemic fungal infections.Acknowledgments
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